Hutchmed/$HCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hutchmed
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Ticker
$HCM
Sector
Primary listing
Employees
1,780
Headquarters
Hong Kong, Hong Kong
Website
Hutchmed Metrics
BasicAdvanced
$2.8B
30.90
$0.53
0.59
-
Price and volume
Market cap
$2.8B
Beta
0.59
52-week high
$19.50
52-week low
$11.51
Average daily volume
54K
Financial strength
Current ratio
4.651
Quick ratio
4.471
Long term debt to equity
5.719
Total debt to equity
8.111
Interest coverage (TTM)
-6.86%
Profitability
EBITDA (TTM)
-7.491
Gross margin (TTM)
8.93%
Net profit margin (TTM)
77.53%
Operating margin (TTM)
-3.27%
Effective tax rate (TTM)
12.61%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-0.81%
Return on equity (TTM)
46.90%
Valuation
Price to earnings (TTM)
30.896
Price to revenue (TTM)
23.265
Price to book
1.67
Price to tangible book (TTM)
1.67
Price to free cash flow (TTM)
-234.85
Free cash flow yield (TTM)
-0.43%
Free cash flow per share (TTM)
-0.07
Growth
Revenue change (TTM)
-1.41%
Earnings per share change (TTM)
-1,178.39%
3-year revenue growth (CAGR)
14.53%
10-year revenue growth (CAGR)
15.75%
3-year earnings per share growth (CAGR)
20.99%
10-year earnings per share growth (CAGR)
15.71%
Bulls say / Bears say
Strong US in-market sales of FRUZAQLA (fruquintinib) reached $130.5 million in H1 2024, demonstrating robust early commercial traction since its November 2023 launch. (FT)
European Commission approval for FRUZAQLA in June 2024 marks HUTCHMED’s first EU authorization, unlocking access to major European oncology markets through its partnership with Takeda. (FT)
The divestment of a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million in January 2025 bolstered HUTCHMED’s balance sheet, providing capital to concentrate on its core oncology pipeline. (Bloomberg)
Philips CEO warns of subdued China sales in 2025 due to intensified government anti-corruption measures disrupting hospital procurement, highlighting potential headwinds for HUTCHMED’s China commercialization. (Reuters)
HUTCHMED’s H1 2024 research and development expenses of $95.3 million represent nearly 31% of total revenue, indicating a high cash burn that may pressure profitability and cash reserves. (FT)
The planned US NDA filing for savolitinib for NSCLC at year-end 2025 is contingent on timely SAVANNAH trial readouts, with any delay risking entry into the critical US lung cancer market. (FT)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hutchmed stock?
Hutchmed (HCM) has a market cap of $2.8B as of September 13, 2025.
What is the P/E ratio for Hutchmed stock?
The price to earnings (P/E) ratio for Hutchmed (HCM) stock is 30.9 as of September 13, 2025.
Does Hutchmed stock pay dividends?
No, Hutchmed (HCM) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Hutchmed dividend payment date?
Hutchmed (HCM) stock does not pay dividends to its shareholders.
What is the beta indicator for Hutchmed?
Hutchmed (HCM) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.